Bristol Myers Squibb selected Houston as the location for a $2.3 billion multi-modal manufacturing campus supporting drug product and finished goods manufacturing from late development through launch. The site is planned to handle multiple modalities, including small molecules, biologics, and antibody-drug conjugates. BMS framed the investment as part of a broader U.S. commitment to invest $40 billion over five years in R&D, technology, and manufacturing. The announcement also places Houston alongside other reshoring commitments tied to tariff risk and national security considerations under Section 232. The report notes that Lilly is also developing a large manufacturing site in Texas and recently acquired CrossBridge Bio, tying the broader regional buildout to next-generation drug substance and advanced modality capacity. For the biotech and pharma supply chain, these campus decisions influence CDMO capacity signals and hiring demand for technical manufacturing talent.